Background Background Hyperprolactinaemia
Hyperprolactinaemia induced by D induced by D 2 2 dopamine receptor dopamine receptor antagonist antipsychotic medication can antagonist antipsychotic medication can result in significant health problems. result in significant health problems.
Aims Aims To examine the role of
To examine the role of DRD2 DRD2 polymorphism on prolactin levels in polymorphism on prolactin levels in patients treated with antipsychotic patients treated with antipsychotic medication. medication.
Method Method Antipsychotic drugs with
Antipsychotic drugs with different degrees of D different degrees of D 2 2 receptor binding receptor binding were given to144 patients with were given to144 patients with schizophrenia. Serum prolactin levels schizophrenia. Serum prolactin levels were obtained and were obtained and Taq Taq1A 1A DRD2 DRD2 alleles alleles were determined. were determined.
Results

Results Prolactin levels increased
Prolactin levels increased across medication groups reflecting across medication groups reflecting increasingly tight D increasingly tight D 2 2 receptor binding receptor binding (clozapine, olanzapine, typical (clozapine, olanzapine, typical antipsychotics and risperidone).In the antipsychotics and risperidone).In the combined medication group, patients with combined medication group, patients with the the DRD2*A1 DRD2*A1allele had 40% higher allele had 40% higher prolactin levels than patients withoutthis prolactin levels than patients withoutthis allele.In patients treated with clozapine allele.In patients treated with clozapine (the loosest D (the loosest D 2 2 receptor binding agent), receptor binding agent), patients with the patients with the DRD2*A1 DRD2*A1allele had allele had prolactin levels twice those of patients prolactin levels twice those of patients without this allele. without this allele.
Conclusions Conclusions Patients withthe
Patients withthe DRD2A1 DRD2A1 allele receiving antipsychotic medications allele receiving antipsychotic medications had higher prolactin levels and were had higher prolactin levels and were overrepresented among those with overrepresented among those with hyperprolactinaemia, suggesting greater hyperprolactinaemia, suggesting greater functional D functional D 2 2 receptor binding in this receptor binding in this group. group.
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Hyperprolactinaemia is a frequent adverse Hyperprolactinaemia is a frequent adverse effect of antipsychotic medication (Petty, effect of antipsychotic medication (Petty, 1999) , and is the result of D 1999), and is the result of D 2 2 dopamine dopamine receptor drug binding (Markianos receptor drug binding (Markianos et al et al, , 2001 ). Hyperprolactinaemia may result in 2001). Hyperprolactinaemia may result in depression, sexual dysfunction, amenordepression, sexual dysfunction, amenorrhoea, galactorrhoea, breast cancer and osrhoea, galactorrhoea, breast cancer and osteoporosis (Maguire, 2002; Halbreich teoporosis (Maguire, 2002; Halbreich et al et al, , 2003 
METHOD METHOD Sample Sample
Patients were recruited at the Fortitude Patients were recruited at the Fortitude Valley Community Mental Health Centre, Valley Community Mental Health Centre, the Royal Brisbane Mental Health Unit the Royal Brisbane Mental Health Unit and the Park Psychiatric Hospital. Inclusion and the Park Psychiatric Hospital. Inclusion criteria were age 18-65 years and meeting criteria were age 18-65 years and meeting DSM-IV criteria for schizophrenia (Ameri-DSM-IV criteria for schizophrenia (American Psychiatric Association, 1994) . Potencan Psychiatric Association, 1994) . Potential participants were excluded if they had tial participants were excluded if they had schizoaffective disorder, bipolar disorder, schizoaffective disorder, bipolar disorder, dementia, organic brain syndrome, major dementia, organic brain syndrome, major depressive disorder with delusions or depressive disorder with delusions or epilepsy. Those who were pregnant were epilepsy. Those who were pregnant were excluded. As a range of psychoactive agents excluded. As a range of psychoactive agents can influence prolactin levels (Jarvinen can influence prolactin levels (Jarvinen et et al al, 1992; Hugues , 1992; Hugues et al et al, 2000; Basturk , 2000; Basturk et et al al, 2001; Keltner , 2001; Keltner et al et al, 2002) , patients reg-, 2002), patients regularly taking antidepressant, opiate, anxioularly taking antidepressant, opiate, anxiolytic or mood-stabilising medication were lytic or mood-stabilising medication were excluded from the study. Potential particiexcluded from the study. Potential participants who nursing or medical staff believed pants who nursing or medical staff believed were not adhering to their medication regiwere not adhering to their medication regimen were also excluded. All participants men were also excluded. All participants provided informed consent and were able provided informed consent and were able to terminate participation without prejuto terminate participation without prejudice. Institutional ethics approval was dice. Institutional ethics approval was obtained from the clinics and hospitals obtained from the clinics and hospitals involved. involved. Kay, 1990 ) was used to assess (PANSS; Kay, 1990 ) was used to assess psychotic symptoms. All raters were trained psychotic symptoms. All raters were trained to a criterion of 90% agreement using to a criterion of 90% agreement using PANSS training videos. Interrater reliability PANSS training videos. Interrater reliability was obtained through random checks of the was obtained through random checks of the PANSS by independent raters of the same PANSS by independent raters of the same patient. These reliabilities were sound. patient. These reliabilities were sound.
Assessments Assessments
Medications Medications
All participants received their prescribed All participants received their prescribed antipsychotic medication for at least 1 antipsychotic medication for at least 1 month at a stable dosage. Thirty-one month at a stable dosage. Thirty-one patients were prescribed clozapine, 31 olanpatients were prescribed clozapine, 31 olanzapine, 33 typical antipsychotics (12 zapine, 33 typical antipsychotics (12 flupentixol, 2 fluphenazine decanoate, 13 flupentixol, 2 fluphenazine decanoate, 13 zuclopenthixol, 3 haloperidol decanoate, 1 zuclopenthixol, 3 haloperidol decanoate, 1 thioridazine, 1 thiothixene and 1 trifluoperthioridazine, 1 thiothixene and 1 trifluoperazine) and 49 risperidone. Antipsychotic azine) and 49 risperidone. Antipsychotic dosage was transformed to chlorpromazine dosage was transformed to chlorpromazine equivalents per kilogram. The mean equivalents per kilogram. The mean chlorpromazine equivalent dosages in the chlorpromazine equivalent dosages in the four medication groups were clozapine four medication groups were clozapine 5.14 mg/kg (s. .00). There was no significant differ-2.00). There was no significant difference in dosage among the four drug groups ence in dosage among the four drug groups ( (F F(3,128) (3,128)¼0.51, 0.51, P P¼0.67). Adherence by 0.67). Adherence by the in-patients was sound as all medication the in-patients was sound as all medication was administered by nursing staff; outwas administered by nursing staff; outpatient adherence was estimated by selfpatient adherence was estimated by selfreport and assessment by the treating psyreport and assessment by the treating psychiatrist. Thirty of the 33 patients receiving chiatrist. Thirty of the 33 patients receiving Prolactin levels and Prolactin levels and DRD2 DRD2 alleles alleles A 10 ml blood sample was drawn from each A 10 ml blood sample was drawn from each participant for DNA extraction and proparticipant for DNA extraction and prolactin determination. The DNA was sent lactin determination. The DNA was sent to the University of California Los Angeles to the University of California Los Angeles for genotyping, and prolactin deterfor genotyping, and prolactin determination was conducted at the Royal mination was conducted at the Royal Brisbane Hospital. Serum prolactin level Brisbane Hospital. Serum prolactin level was determined by a heterogeneous sandwas determined by a heterogeneous sandwich magnetic separation assay (Immuno wich magnetic separation assay (Immuno 1 system; Bayer Diagnostics, Newbury, 1 system; Bayer Diagnostics, Newbury, Berkshire, UK) which was standardised Berkshire, UK) which was standardised against the World Health Organization against the World Health Organization 3rd IRP 84/500 Reference Manual. 3rd IRP 84/500 Reference Manual. DNA was extracted from leucocytes DNA was extracted from leucocytes using standard techniques and subsequently using standard techniques and subsequently used as a template for determination of used as a template for determination of Taq Taq1A 1A DRD2 DRD2 alleles by the polymerase alleles by the polymerase chain reaction (Grandy chain reaction (Grandy et al et al, 1993) . As , 1993). As previously described (Noble previously described (Noble et al et al, 1994) , , 1994), the amplification of DNA was carried out the amplification of DNA was carried out using a Perkin Elmer GeneAmp 9600 using a Perkin Elmer GeneAmp 9600 thermocycler (Perkin Elmer, Boston, MA, thermocycler (Perkin Elmer, Boston, MA, USA). Approximately 500 ng of amplified USA). Approximately 500 ng of amplified DNA was then digested with 5 units of DNA was then digested with 5 units of Taq Taq1 restriction enzyme (Gibco/BRL, 1 restriction enzyme (Gibco/BRL, Grand Island, NY, USA) at 65 Grand Island, NY, USA) at 658 8C overnight.
C overnight. The resulting products were analysed by The resulting products were analysed by electrophoresis in a 2.5% agarose gel electrophoresis in a 2.5% agarose gel containing ethidium bromide and visualised containing ethidium bromide and visualised under ultraviolet light. 
Data analysis Data analysis
Information coded from interview proInformation coded from interview proformas was entered into a computer dataformas was entered into a computer database along with prolactin results. The base along with prolactin results. The Taq Taq1A 1A DRD2 DRD2 allelic data were entered allelic data were entered last. Chi-squared tests (Yates' corrected) last. Chi-squared tests (Yates' corrected) were employed to compare differences in were employed to compare differences in categorical variables between categorical variables between A1 A1 + + and and A1 A1 7 7 allelic groups. Analysis of variance allelic groups. Analysis of variance (ANOVA) was used to compare differences (ANOVA) was used to compare differences in prolactin levels among the various drug in prolactin levels among the various drug groups. Similarly, one-way ANOVA was groups. Similarly, one-way ANOVA was employed to examine differences in prolacemployed to examine differences in prolactin levels between the tin levels between the A1 A1 
RESULTS RESULTS
The results confirmed a significant gender The results confirmed a significant gender effect in prolactin levels of patients treated effect in prolactin levels of patients treated with antipsychotic medications. Female with antipsychotic medications. Female participants had significantly higher proparticipants had significantly higher prolactin levels than males ( lactin levels than males (F F(1,142) 
¼374). 374).
Men and women were equally represented Men and women were equally represented across the four medication groups. across the four medication groups.
Analysis of variance revealed significant Analysis of variance revealed significant differences in prolactin levels among the differences in prolactin levels among the four medication groups ( four medication groups (F F(3,140) (3,140)¼19.0, 19.0, P P5 50.0001). Figure 1 shows prolactin levels 0.0001). Figure 1 shows prolactin levels in each of the treatment groups. in each of the treatment groups. Post hoc Post hoc pairwise comparisons were undertaken to pairwise comparisons were undertaken to test differences between groups. Olanzatest differences between groups. Olanzapine compared with clozapine treatment pine compared with clozapine treatment resulted in significantly higher prolactin resulted in significantly higher prolactin levels ( levels (F F(1,60) (1,60)¼4.76, 4.76, P P¼0.033). Patients 0.033). Patients treated with typical antipsychotics had treated with typical antipsychotics had significantly higher prolactin levels than significantly higher prolactin levels than their olanzapine-treated counterparts their olanzapine-treated counterparts ( (F F(1,62) (1,62)¼7.60, 7.60, P P¼0.007). Finally, signifi-0.007). Finally, significantly higher levels of prolactin were evident cantly higher levels of prolactin were evident in patients treated with risperidone compared in patients treated with risperidone compared with those treated with typical antipsychotics with those treated with typical antipsychotics ( (F F(1,80) (1,80)¼8.97, 8.97, P P¼0.004). 0.004). The genotypes of the 144 patients were The genotypes of the 144 patients were as follows: as follows: A1/A1 A1/A1 ( (n n¼7), 7), A1/A2 A1/A2 ( (n n¼55) 55) and and A2/A2 A2/A2 ( (n n¼82). The mean age of the 82 Analysis of variance of the total sample of Analysis of variance of the total sample of patients indicated that those carrying the patients indicated that those carrying the A1 A1 allele had about a 40% higher prolactin allele had about a 40% higher prolactin level than patients without this allele level than patients without this allele ( (F F(1,142) (1,142)¼4.50, 4.50, P P¼0.04). 0.04). Clozapine, the loosest-binding antiClozapine, the loosest-binding antipsychotic drug, showed a significant psychotic drug, showed a significant difference across allelic groups, with a difference across allelic groups, with a 14 8 14 8
Fig. 1 Fig. 1 Hyperprolactinaemia is defined using Hyperprolactinaemia is defined using community sample cut-off levels set at a community sample cut-off levels set at a 95% reference range: 95% reference range: 5 5430 mU/l in men 430 mU/l in men and and 5 5560 mU/l in women (Vanderpump 560 mU/l in women (Vanderpump et al et al, 1998) . In total, 64 patients, 44% of , 1998). In total, 64 patients, 44% of the sample, exceeded these levels. Only 7 the sample, exceeded these levels. Only 7 of these patients were prescribed lowerof these patients were prescribed lowerbinding agents (clozapine and olanzapine) binding agents (clozapine and olanzapine) confirming that these medications are confirming that these medications are rarely associated with hyperprolactinaemia rarely associated with hyperprolactinaemia (5% of the sample). Forty of the patients (5% of the sample). Forty of the patients on risperidone exceeded these prolactin leon risperidone exceeded these prolactin levels, indicating that 81% of patients on this vels, indicating that 81% of patients on this medication were in the hyperprolactinmedication were in the hyperprolactinaemic range. A Yates'-corrected aemic range. A Yates'-corrected w w 2 2 analysis analysis conducted to compare allelic status in the conducted to compare allelic status in the group with prolactin levels in the normal group with prolactin levels in the normal range and those with hyperprolactinaemia range and those with hyperprolactinaemia was significant ( was significant (w w 
DISCUSSION DISCUSSION
Prolactin response to antipsychotic mediProlactin response to antipsychotic medication was greatest in patients prescribed cation was greatest in patients prescribed risperidone. Prolactin response was succesrisperidone. Prolactin response was successively lower in patients administered typical sively lower in patients administered typical antipsychotics, olanzapine and clozapine. antipsychotics, olanzapine and clozapine. This order across medications has also been This order across medications has also been found in positron emission tomography found in positron emission tomography binding studies (e.g. dopamine receptor dopamine receptor occupancy corresponded to serum prolactin occupancy corresponded to serum prolactin levels. Prolactin levels were higher in levels. Prolactin levels were higher in women than in men. women than in men.
Individuals with the Individuals with the A1 A1 allele and allele and higher prolactin levels when treated with higher prolactin levels when treated with antipsychotic medication and were overantipsychotic medication and were overrepresented among patients with clinical represented among patients with clinical hyperprolactinaemia. The hyperprolactinaemia. The A1 A1 + + participants participants also had significantly higher prolactin levels also had significantly higher prolactin levels than than A1 A1 2 receptor density is receptor density is also important in determining prolactin also important in determining prolactin response to antipsychotic agents. response to antipsychotic agents.
Individuals with the Individuals with the A1 A1 allele have a reallele have a reduced density of brain D duced density of brain D 2 2 receptors (Noble receptors (Noble et al et al, 1991; Thompson , 1991; Thompson et al et al, 1997; Phjalai-, 1997; Phjalainen nen et al et al, 1998; Jonsson , 1998; Jonsson et al et al, 1999 ). An , 1999 ). An early brain autopsy study (Noble early brain autopsy study (Noble et al et al, , 1991) (Nordstrom et al et al, 1993) . A trend towards improved , 1993). A trend towards improved efficacy in patients with treatment-resistant efficacy in patients with treatment-resistant schizophrenia was found when doses of schizophrenia was found when doses of olanzapine were increased to an average olanzapine were increased to an average of 30.4 mg (Volavka of 30.4 mg (Volavka et al et al, 2002) . Prelimin-, 2002) . Preliminary investigations have been undertaken to ary investigations have been undertaken to increase the efficacy of clozapine, an agent increase the efficacy of clozapine, an agent with a high D with a high D 2 2 receptor dissociation conreceptor dissociation constant or loose binding, by adding halostant or loose binding, by adding haloperidol, an agent with a low dissociation peridol, an agent with a low dissociation constant (Kapur constant (Kapur et al et al, 2001) . Individuals , 2001). Individuals lacking the lacking the A1 A1 allele may be more likely allele may be more likely to benefit from these approaches to to benefit from these approaches to improve drug D improve drug D 2 2 receptor occupancy given receptor occupancy given that they may have relatively more free, that they may have relatively more free, unbound, D unbound, D 2 2 receptors. Conversely, receptors. Conversely, A1 A1 + + individuals are unlikely to derive as much individuals are unlikely to derive as much improvement from this approach, with improvement from this approach, with optimal therapeutic effect being likely at optimal therapeutic effect being likely at lower dosages in these patients. Patients lower dosages in these patients. Patients lacking the lacking the A1 A1 allele may require higher allele may require higher doses for maximal antipsychotic effect, doses for maximal antipsychotic effect, particularly when prescribed a loosely bindparticularly when prescribed a loosely binding antipsychotic such as clozapine or ing antipsychotic such as clozapine or quetiapine. quetiapine.
According to the rapid dissociation According to the rapid dissociation model (Kapur & Seeman, 2001 ), loosemodel (Kapur & Seeman, 2001 ), loosebinding atypical agents are hypothesised binding atypical agents are hypothesised to have an antipsychotic action without to have an antipsychotic action without causing other effects of dopamine blockade causing other effects of dopamine blockade such as raised prolactin levels or extrapyrasuch as raised prolactin levels or extrapyramidal side-effects (Kapur & Seeman, 2001) . midal side-effects (Kapur & Seeman, 2001) . Our data are not consistent with this, Our data are not consistent with this, 14 9 14 9 
Limitations of the study Limitations of the study
Although the total number of patients Although the total number of patients investigated is adequate, one of the limitainvestigated is adequate, one of the limitations of this study is the relatively small tions of this study is the relatively small number of patients in each medication subnumber of patients in each medication subgroup. Further research involving larger group. Further research involving larger numbers of patients with each individual numbers of patients with each individual medication is indicated in order to ascertain medication is indicated in order to ascertain whether or not this association occurs with whether or not this association occurs with specific antipsychotic agents. Prospective specific antipsychotic agents. Prospective studies examining the changes in prolactin studies examining the changes in prolactin levels over time are also recommended. levels over time are also recommended.
Implications of the study Implications of the study 
The effects of olanzapine, risperidone, and haloperidol The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. on plasma prolactin levels in patients with schizophrenia. Clinical Therapeutics Clinical Therapeutics, , 9 9, 1085^1096. , 1085^1096. Patients with the DRD2*A1 DRD2*A1 allele treated with antipsychotic medications had allele treated with antipsychotic medications had higher prolactin levels than patients without this allele, and a higher percentage of higher prolactin levels than patients without this allele, and a higher percentage of patients with the patients with the DRD2*A1 DRD2*A1 allele compared with patients without this allele had allele compared with patients without this allele had hyperprolactinaemia. hyperprolactinaemia.
& & The
The A1 A1 allele of allele of DRD2 DRD2 may be a useful clinical marker for identification for those at may be a useful clinical marker for identification for those at risk of hyperprolactinaemia and associated adverse effects. risk of hyperprolactinaemia and associated adverse effects. Prospective studies examining changes in prolactin levels over time are indicated. 
